{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T18:16:05Z","timestamp":1782324965129,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"DOI":"10.7759\/cureus.83243","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T10:54:43Z","timestamp":1746010483000},"source":"Crossref","is-referenced-by-count":2,"title":["Statins and Thyroid Eye Disease: A Propensity Score-Matched Retrospective Cohort Analysis"],"prefix":"10.7759","author":[{"given":"Maxim J","family":"Barnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Casipit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Rivadeneira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4274\/tjo.80688","article-title":"Thyroid-associated ophthalmopathy","volume":"47","author":"\u015eahl\u0131 E","year":"2017","unstructured":"\u015eahl\u0131 E, G\u00fcnd\u00fcz K. Thyroid-associated ophthalmopathy. Turk J Ophthalmol. 2017, 47:94-105. 10.4274\/tjo.80688","journal-title":"Turk J Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.121815","article-title":"Thyroid eye disease","volume":"185","author":"Belliveau MJ","year":"2013","unstructured":"Belliveau MJ, Jordan DR. Thyroid eye disease. CMAJ. 2013, 185:797. 10.1503\/cmaj.121815","journal-title":"CMAJ"},{"key":"ref3","unstructured":"Thyroid eye disease. (2023). Accessed. March 24, 2025: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK582134\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2011.11.007","article-title":"Evaluating Graves' orbitopathy","volume":"26","author":"Dolman PJ","year":"2012","unstructured":"Dolman PJ. Evaluating Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012, 26:229-48. 10.1016\/j.beem.2011.11.007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena L","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, et al.. The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol. 2021, 185:G43-67. 10.1530\/EJE-21-0479","journal-title":"Eur J Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101348","article-title":"Effects of teprotumumab on patients with long-standing, active thyroid eye disease","volume":"26","author":"Vinson KB","year":"2022","unstructured":"Vinson KB, Kirzhner M. Effects of teprotumumab on patients with long-standing, active thyroid eye disease. Am J Ophthalmol Case Rep. 2022, 26:101348. 10.1016\/j.ajoc.2022.101348","journal-title":"Am J Ophthalmol Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.5103","article-title":"Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease","volume":"133","author":"Stein JD","year":"2015","unstructured":"Stein JD, Childers D, Gupta S, et al.. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol. 2015, 133:290-6. 10.1001\/jamaophthalmol.2014.5103","journal-title":"JAMA Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab070","article-title":"Statins decrease the risk of orbitopathy in newly diagnosed patients with Graves' disease","volume":"106","author":"Nilsson A","year":"2021","unstructured":"Nilsson A, Tsoumani K, Planck T. Statins decrease the risk of orbitopathy in newly diagnosed patients with Graves' disease. J Clin Endocrinol Metab. 2021, 106:1325-32. 10.1210\/clinem\/dgab070","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2024.0536","article-title":"Statin use and the risk of graves\u2019 orbitopathy: a nationwide population-based cohort study","volume":"35","author":"Chou YT","year":"2025","unstructured":"Chou YT, Lai CC, Li CY, et al.. Statin use and the risk of graves\u2019 orbitopathy: a nationwide population-based cohort study. Thyroid. 2025, 35:199-207. 10.1089\/thy.2024.0536","journal-title":"Thyroid"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02513-z","article-title":"Sex-specific risk factors associated with Graves' orbitopathy in Korean patients with newly diagnosed graves' disease","volume":"37","author":"Lee J","year":"2023","unstructured":"Lee J, Kang J, Ahn HY, Lee JK. Sex-specific risk factors associated with Graves' orbitopathy in Korean patients with newly diagnosed graves' disease. Eye (Lond). 2023, 37:3382-91. 10.1038\/s41433-023-02513-z","journal-title":"Eye (Lond)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-024-00930-1","article-title":"An appraisal of the preventive effect of statins on the development of graves\u2019 ophthalmopathy: a hospital-based cohort study","volume":"13","author":"Hsu GC","year":"2024","unstructured":"Hsu GC, Shih SR, Chang FY, Liao SL, Wei YH. An appraisal of the preventive effect of statins on the development of graves\u2019 ophthalmopathy: a hospital-based cohort study. Ophthalmol Ther. 2024, 13:1499-511. 10.1007\/s40123-024-00930-1","journal-title":"Ophthalmol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2018.04.009","article-title":"The effect of oral statin therapy on strabismus in patients with thyroid eye disease","volume":"22","author":"Reynolds AL","year":"2018","unstructured":"Reynolds AL, Del Monte MA, Archer SM. The effect of oral statin therapy on strabismus in patients with thyroid eye disease. J AAPOS. 2018, 22:340-3. 10.1016\/j.jaapos.2018.04.009","journal-title":"J AAPOS"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(21)00238-2","article-title":"\u2018Statins for graves\u2019 orbitopathy (STAGO): a phase 2, open-label, adaptive, single Centre, randomised clinical trial\u2019","volume":"9","author":"Lanzolla G","year":"2021","unstructured":"Lanzolla G, Sabini E, Leo M, et al.. \u2018Statins for graves\u2019 orbitopathy (STAGO): a phase 2, open-label, adaptive, single Centre, randomised clinical trial\u2019. Lancet Diabet. 2021, 9:733-42. 10.1016\/s2213-8587(21)00238-2","journal-title":"Lancet Diabet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker PM","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, et al.. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359:2195-207. 10.1056\/NEJMoa0807646","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-018-9478-8","article-title":"Statins, metformin, proprotein-convertase-subtilisin-Kexin type-9 (PCSK9) inhibitors and sex hormones: immunomodulatory properties?","volume":"19","author":"Koch CA","year":"2018","unstructured":"Koch CA, Krabbe S, Hehmke B. Statins, metformin, proprotein-convertase-subtilisin-Kexin type-9 (PCSK9) inhibitors and sex hormones: immunomodulatory properties?. Rev Endocr Metab Disord. 2018, 19:363-95. 10.1007\/s11154-018-9478-8","journal-title":"Rev Endocr Metab Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/355876-statins-and-thyroid-eye-disease-a-propensity-score-matched-retrospective-cohort-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T10:54:44Z","timestamp":1746010484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/355876-statins-and-thyroid-eye-disease-a-propensity-score-matched-retrospective-cohort-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.83243","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,30]]}}}